Mirum Pharmaceuticals (MIRM) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year price targets for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $84.00. On average, they expect the company's stock price to reach $53.33 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts.

Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM stock has increased by 57.5% and is now trading at $30.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our MIRM earnings forecast.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $0.11. The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $30 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 103.59% and a negative net margin of 152.27%.

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

(MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Mirum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (9.03%), BlackRock Inc. (5.30%), Rock Springs Capital Management LP (4.75%), State Street Corp (3.90%), Cadian Capital Management LP (3.30%) and Polar Capital Holdings Plc (2.42%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends.

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MIRM stock can currently be purchased for approximately $30.72.

Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $1.18 billion and generates $77.06 million in revenue each year. The company earns $-135,660,000.00 in net income (profit) each year or ($4.75) on an earnings per share basis.

The company employs 213 workers across the globe.

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com.